Ona Therapeutics, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, is a biotechnology company focused on the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The company was established as a spin-off from ICREA and the IRB Barcelona (Institute for Research in Biomedicine). By leveraging cutting-edge research in cancer biology and metabolism, Ona Therapeutics aims to develop innovative treatments to prevent metastasis and improve outcomes for cancer patients.